Published in Hepatitis Weekly, December 17th, 2001
Rebetol and Intron A constitute the first combination therapy approved in Japan for treating chronic hepatitis C. Rebetol will be launched in Japan upon receiving pricing approval.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.